Basic Oxsoralen Information

• INN (International Nonproprietary Name): Methoxsalen
• Brand names available in United Kingdom: Oxsoralen, Uvadex
• ATC Code: L01XD03
• Forms & dosages: Capsule 10 mg, Solution for IV
• Manufacturers in United Kingdom: Uvadex as manufacturer reference; international supply linked to Temmler, Meda, Pierre Fabre, Valeant, Mylan, Mallinckrodt, and Consilient/Clonmel
• Registration status in United Kingdom: MHRA-regulated prescription-only medicine, included in the British National Formulary
• OTC / Rx classification: Prescription Only (Rx) in all sampled countries

Key Findings From Recent Trials

Wondering why oxsoralen still has a place when newer options keep appearing?

Recent literature from 2022 to 2025 points to a narrower but still important role for methoxsalen in specialist care.

In UK phototherapy units, PUVA therapy remains a useful option for refractory psoriasis and vitiligo when newer non-psoralen approaches fail, are unavailable, or are not suitable for the patient.

That same specialist pathway also keeps methoxsalen relevant in extracorporeal photopheresis for cutaneous T-cell lymphoma.

Across recent studies and practice updates, the message is consistent: methoxsalen is not a broad community medicine, but a protocol-led treatment used in selected patients.

Adult oral dosing commonly sits around 0.6 mg/kg for psoriasis and 0.4 to 0.6 mg/kg for vitiligo, with UVA given 1.5 to 2 hours later.

Schedules are usually 2 to 4 sessions a week, with the response judged by visible skin improvement and the patient’s tolerance.

Safety discussions now focus more heavily on cumulative UVA exposure, skin ageing, and long-term malignancy surveillance.

The biggest immediate safety signal remains phototoxicity, especially if timing, dose, or sun-avoidance advice is missed.

That is why methoxsalen, Oxsoralen, and Uvadex are still handled in specialist settings rather than routine primary care.

Clinical Mechanism Of Action

People often ask what a psoralen actually does to the skin.

Methoxsalen is a psoralen that makes skin cells more sensitive to UVA light.

Used correctly, it helps slow abnormal skin-cell turnover and can reduce depigmented or inflamed patches during controlled photochemotherapy.

Its scientific names include 8-MOP, 8-methoxypsoralen, and xanthotoxin, and the ATC code is L01XD03.

After oral dosing, the compound intercalates with DNA and, once activated by UVA, forms photoadducts that alter cell proliferation and immune signalling.

That mechanism is the basis of PUVA, which combines psoralen plus UVA in a carefully supervised treatment pathway.

In UK practice, methoxsalen photochemotherapy is mainly used in dermatology and selected haematology pathways rather than as general prescribing.

Scope Of Approved And Off-Label Use

Is oxsoralen available in the UK, and what is it actually prescribed for?

In the United Kingdom, methoxsalen is prescription only and regulated by the MHRA, with reference in the BNF.

UK brand names include Oxsoralen and Uvadex, and the common forms are 10 mg capsules and solution for IV use.

The specialist uses that matter most are psoriasis, vitiligo, and cutaneous T-cell lymphoma via photopheresis protocols.

Those uses are not considered routine community prescribing because UVA equipment, monitoring, and counselling are all part of the treatment.

The restriction reflects risk management rather than lack of biological activity.

Some EU and EEA markets have limited or withdrawn indications because of safety concerns, and that same caution shapes UK specialist use.

For a patient who has already tried topical therapy, narrowband UVB, or other standard approaches, methoxsalen may still be the next step in a hospital phototherapy unit.

In our online pharmacy, oxsoralen is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Dosage Strategy

How is methoxsalen timed, and why does the clock matter so much?

Oral methoxsalen is usually taken 1.5 to 2 hours before UVA.

That gap matters because the treatment only works as planned when the skin is exposed at the right point in the dosing window.

Adults are generally dosed by weight, with higher exposure avoided unless there is a clear specialist reason.

Weight-based oral PUVA dosing is commonly set out as follows:

• Under 30 kg: 10 mg
• 30 to 50 kg: 20 mg
• 51 to 65 kg: 30 mg
• 66 to 80 kg: 40 mg
• 81 to 90 kg: 50 mg
• 91 to 115 kg: 60 mg
• Over 115 kg: 70 mg

For psoriasis, the usual adult oral dose is around 0.6 mg/kg, rounded down.

For vitiligo, the dose is typically 0.4 to 0.6 mg/kg.

For cutaneous T-cell lymphoma, the dose is individualized within a photopheresis protocol.

Children are rarely treated and are generally avoided because of long-term carcinogenesis concerns.

Elderly patients should start at the lowest practical dose and be monitored closely for phototoxicity.

Hepatic impairment raises toxicity concern, and severe impairment is generally a reason to avoid treatment.

Safety Protocols

What should patients and staff watch for before the first UVA session?

Contraindications include photosensitivity disorders such as lupus and porphyria, previous melanoma or non-melanoma skin cancer, aphakia, pregnancy and breastfeeding, and hypersensitivity to methoxsalen or other psoralens.

Common adverse effects include redness, itching, dry skin, mild swelling, headache, nausea, and nervousness.

More troublesome reactions can include blistering, peeling, and marked photosensitisation.

Long-term concerns are skin ageing, freckling, and an increased cancer risk with cumulative exposure.

The central safety issue is not just the capsule itself, but the capsule-plus-UVA combination.

That is why timing, counselling, and supervision matter so much in PUVA therapy.

If the dose or light session is mistimed, phototoxicity can become severe very quickly.

Patients should also be told clearly to follow sun-avoidance instructions after treatment, because even normal daylight can become an issue if precautions are missed.

Interaction Mapping

Does methoxsalen have a major food interaction?

Food is not the main issue here.

The critical point is timing with UVA and avoiding accidental light exposure after dosing.

Taking methoxsalen without the planned light session can still be risky if the person then walks into strong sunlight, sits in direct sun, or uses a sunbed.

Other photosensitising medicines can raise the risk further.

That includes any treatment that increases sun sensitivity or makes the skin less able to recover from light injury.

Practical UK advice is straightforward: avoid sunbeds, avoid direct midday sun, and avoid unprotected windows after taking the capsule.

All prescribed and over-the-counter medicines should be reviewed before treatment starts, especially in patients already taking dermatology medicines.

Patient Experience Analysis

What do patients usually notice first when they start PUVA?

In specialist phototherapy services, patients tend to continue when they can see plaques settling or depigmented patches improving.

Adherence is strongest when the purpose of the treatment, the timing of the capsule, and the sun-avoidance steps are explained clearly.

Many people say the capsule itself is easy enough to take.

The real burden is fitting in the UVA sessions around work, family, and hospital travel.

That is why a Friday evening or early-morning appointment can make a big difference to whether the course is kept up.

Skin tenderness and lifestyle restriction are the frustrations most often mentioned in patient discussions.

In the UK, travel to hospital phototherapy units can be a genuine barrier, especially for people outside major cities.

Patients also worry about cancer risk, so reassurance needs to be balanced and evidence-led rather than brushed aside.

Distribution And Pricing Landscape

How easy is it to get Oxsoralen in the UK?

In the United Kingdom, Oxsoralen and Uvadex are specialist-prescribed products, usually supplied through hospital or pharmacy supply chains rather than routine high-street dispensing.

The common forms are 10 mg capsules and solution for IV use.

Brand availability varies by country, and the names Oxsoralen and Uvadex appear across several European and international markets.

Manufacturing and distribution can involve Temmler, Meda, Pierre Fabre, Valeant, Mylan, Mallinckrodt, and Consilient/Clonmel, depending on the market.

Pricing is driven more by specialist access and supply continuity than by consumer competition.

People searching online often use terms such as Oxsoralen tablets 10mg or Uvadex solution for photopheresis.

That said, supply should always be checked against the exact formulation needed for the specialist pathway.

Alternative Options

What happens if methoxsalen is not the best fit?

There are several alternatives, and in routine dermatology they are often tried first.

Trimethylpsoralen, also called trioxsalen or INN Trisoralen, is another psoralen option, though it is less commonly used.

Narrowband UVB therapy is a non-psoralen light option for psoriasis and vitiligo.

Calcipotriol is a psoriasis-focused topical alternative.

Tacrolimus can be useful in selected vitiligo cases and inflammatory dermatoses.

In simple terms:

• Methoxsalen is strongest where PUVA therapy is the chosen pathway.
• Narrowband UVB avoids systemic psoralen exposure.
• Topical treatments are easier to access and need less monitoring.

That is why methoxsalen is usually reserved for refractory disease or specialist protocols rather than routine first-line use.

Regulatory Status

Is methoxsalen really prescription only everywhere?

Yes, in the sampled markets it is a prescription-only medicine.

In the UK, methoxsalen is MHRA-regulated and included in the British National Formulary.

Across the EEA and EU, it is also prescription only, although some indications may be limited or withdrawn because of safety concerns.

In the USA, it is FDA-approved for PUVA use in vitiligo, psoriasis, and cutaneous T-cell lymphoma.

Canada markets Oxsoralen and Uvadex as Rx-only products, and Australia registers it as a prescription medicine.

That regulatory caution reflects the known phototoxicity and carcinogenicity risks.

In UK practice, it supports hospital-led dispensing, documented consent, and specialist follow-up.

Consolidated FAQ

What is Oxsoralen?

It is a brand name for methoxsalen, a psoralen used with UVA in PUVA therapy.

What is it used for?

Its main specialist uses are psoriasis, vitiligo, and selected cutaneous T-cell lymphoma protocols.

How is it taken?

It is usually taken 1.5 to 2 hours before UVA, with adult dosing based on body weight.

Is it available in the UK?

Yes, as a specialist prescription-only medicine, including Oxsoralen and Uvadex.

Can patients go into the sun after dosing?

They should avoid unprotected sunlight and follow the phototherapy unit’s advice very closely.

Visual Guide

A simple clinic graphic often helps patients understand the workflow without too much text.

Treatment timeline:

1. Prescription review and baseline screening.
2. Take the methoxsalen capsule.
3. Wait 1.5 to 2 hours.
4. Attend the controlled UVA session.
5. Follow sun-avoidance advice for the rest of the day.

Risk map:

• Lower risk: protocol-led use in specialist units.
• Higher risk: missed timing, extra sunlight exposure, and poor counselling.

For UK patients, the most helpful visual usually shows the weight-based dose, the UVA timing, warning signs of phototoxicity, and when to call the unit.

Storage And Transport

How should oxsoralen be kept at home or in clinic stock?

Store below 25°C.

Keep it protected from light, moisture, and excessive heat.

Leave it in the original packaging until it is needed.

Transport should follow standard oral solid or solution handling rules.

Because phototherapy medicines are often used infrequently, they can sit unused for long periods, so expiry dates should be checked carefully before a clinic session.

That small step helps avoid cancelled appointments and wasted specialist time.

Guidelines For Proper Use

What makes methoxsalen safer and more effective in practice?

It should only be used under specialist supervision.

The dose, the UVA timing, and the skin-type protocol all need to match precisely.

Cumulative exposure and clinical response should be documented through the course.

Before treatment:

• Confirm there are no contraindications.
• Review photosensitising medicines.
• Explain sun-avoidance and eye protection.
• Check pregnancy and breastfeeding status.

During treatment:

• Give the capsule at the correct interval before UVA.
• Follow the unit’s phototherapy parameters exactly.

After treatment:

• Watch for erythema, blistering, or severe tenderness.
• If a dose is missed and UVA cannot be rebooked the same day, skip it rather than doubling.

This is not a self-care medicine.

The safest outcomes come from hospital phototherapy units with clear counselling and follow-up.

Delivery Across United Kingdom

Final Takeaway

Oxsoralen still has a clear place in UK specialist care when PUVA is the right tool for the job.

It is most relevant for refractory psoriasis, vitiligo, and photopheresis protocols in cutaneous T-cell lymphoma.

The benefits can be meaningful, but only when dosing, UVA timing, and sun-avoidance advice are followed properly.

That is why methoxsalen is best viewed as a specialist medicine rather than an everyday pharmacy item.

If treatment is being considered, the safest route is a dermatology or haematology-led plan with full counselling and monitoring.